MICROPATHOLOGY LIMITED

Their core work

Micropathology is a UK-based diagnostics SME specializing in molecular detection and characterization of infectious diseases. They provide laboratory expertise in pathogen identification, particularly for febrile illnesses where distinguishing bacterial from viral infection is critical for treatment decisions. Their work spans point-of-care diagnostic platform development to RNA-based personalised molecular signature diagnosis, bridging the gap between laboratory science and clinical decision-making in infection management.

What they specialise in

How they've shifted over time

Micropathology's trajectory shows a clear deepening from general infectious disease diagnostics toward personalised molecular approaches. Their earliest project (PoC-ID, 2015) focused on building ultra-sensitive point-of-care hardware platforms, while PERFORM (2016) shifted toward clinical decision-making — using biomarkers to differentiate bacterial from viral febrile illness. Their most recent and largest project, DIAMONDS (2020), represents a further leap into RNA-based personalised molecular signatures, suggesting a move toward precision diagnostics and host-response profiling rather than simple pathogen detection.

Micropathology is moving from pathogen detection toward host-response molecular profiling, positioning them for the next generation of precision infection diagnostics.

How they like to work

Micropathology consistently operates as a specialist participant rather than a project leader, contributing targeted diagnostic expertise to large European consortia. With 44 unique partners across 16 countries from just 3 projects, they work in broad, multi-national teams — typical of large-scale clinical validation studies. Their consistent participant role and growing funding per project (EUR 118K to 550K) suggest they are a trusted technical contributor whose role expands as consortia recognise their value.

Despite only three projects, Micropathology has built a remarkably broad network of 44 partners across 16 countries, reflecting their involvement in large clinical consortia that require multi-site validation across European healthcare systems.

What sets them apart

As a private SME with deep molecular diagnostics capability, Micropathology occupies a rare niche: a small commercial lab that can contribute clinical-grade diagnostic validation to large research consortia. Unlike university labs, they bring a commercial perspective on diagnostic feasibility and scalability. Their decade-long track record in febrile illness diagnostics — from PoC-ID through PERFORM to DIAMONDS — gives them continuity and accumulated expertise that few SMEs in this space can match.

Highlights from their portfolio

• DIAMONDS
  Their largest project (EUR 550K), running until 2026, representing their most advanced work in RNA-based personalised molecular diagnosis of febrile illness.
• PERFORM
  A 5-year multi-centre study addressing the critical clinical challenge of distinguishing bacterial from viral infection to reduce unnecessary antibiotic use.